ACER Acer Therapeutics Inc

Price (delayed)

$0.75

Market cap

$12.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.43

Enterprise value

$13.98M

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ...

Highlights

Acer Therapeutics's debt has decreased by 3.9% QoQ

The company's quick ratio has shrunk by 63% QoQ and by 34% YoY

Acer Therapeutics's gross profit has shrunk by 60% YoY

Sector: Healthcare

Industry: Biotechnology

Website: https://acertx.com/

Peers: NRC NWBO

Key stats

What are the main financial stats of ACER

Market

Shares outstanding

16.37M

Market cap

$12.28M

Enterprise value

$13.98M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

33.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

38.84

Earnings

Revenue

$360,000

EBIT

-$21.15M

EBITDA

-$21.08M

Free cash flow

-$23.43M

Per share

EPS

-$1.43

Free cash flow per share

-$1.46

Book value per share

-$0.77

Revenue per share

$0.02

TBVPS

$0.48

Balance sheet

Total assets

$15.32M

Total liabilities

$27.53M

Debt

$8.08M

Equity

-$12.21M

Working capital

-$13.49M

Liquidity

Debt to equity

-0.66

Current ratio

0.35

Quick ratio

0.31

Net debt/EBITDA

-0.08

Margins

EBITDA margin

-5,854.4%

Gross margin

100%

Net margin

-5,909.3%

Operating margin

-6,603%

Efficiency

Return on assets

-80.1%

Return on equity

N/A

Return on invested capital

N/A

Return on capital employed

N/A

Return on sales

-5,874.5%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ACER stock price

How has the Acer Therapeutics stock price performed over time

Intraday

-2.85%

1 week

11.94%

1 month

-64.95%

1 year

-74.83%

YTD

-70.12%

QTD

-70.12%

Financial performance

How have Acer Therapeutics's revenue and profit performed over time

Revenue

$360,000

Gross profit

$360,000

Operating income

-$23.77M

Net income

-$21.27M

Gross margin

100%

Net margin

-5,909.3%

Acer Therapeutics's gross profit has shrunk by 60% YoY

Acer Therapeutics's revenue has plunged by 60% YoY

The company's operating income fell by 34% YoY and by 9% QoQ

The company's net income fell by 24% YoY and by 9% QoQ

Growth

What is Acer Therapeutics's growth rate over time

Valuation

What is Acer Therapeutics stock price valuation

P/E

N/A

P/B

N/A

P/S

33.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

38.84

ACER's EPS is down by 13% YoY and by 6% from the previous quarter

Acer Therapeutics's equity has decreased by 39% from the previous quarter

Acer Therapeutics's revenue has plunged by 60% YoY

The price to sales (P/S) is 48% lower than the last 4 quarters average of 64.2

Efficiency

How efficient is Acer Therapeutics business performance

ACER's ROS has plunged by 199% YoY and by 9% from the previous quarter

Acer Therapeutics's return on assets has shrunk by 53% YoY and by 27% QoQ

Dividends

What is ACER's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ACER.

Financial health

How did Acer Therapeutics financials performed over time

Acer Therapeutics's total assets is 44% lower than its total liabilities

The company's quick ratio has shrunk by 63% QoQ and by 34% YoY

Acer Therapeutics's current ratio has shrunk by 60% QoQ and by 57% YoY

Acer Therapeutics's debt is 166% higher than its equity

Acer Therapeutics's equity has decreased by 39% from the previous quarter

Acer Therapeutics's debt to equity has increased by 31% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.